Literature DB >> 6203528

Characterization of the RNA dependent DNA polymerase of a new human T-lymphotropic retrovirus (lymphadenopathy associated virus).

M A Rey, B Spire, D Dormont, F Barre-Sinoussi, L Montagnier, J C Chermann.   

Abstract

We described here the characteristics of the Reverse Transcriptase activity associated with the Lymphadenopathy Associated Virus ( LAV ). A critical concentration of non ionic detergent, all four deoxyribonucleosides triphosphates and the divalent cation Mg2+ are required for optimal endogenous enzyme activity. The endogenous reaction product is digested by DNase and not by RNase and its synthesis is only slightly inhibited by actinomycin D. Exogenous reactions are optimal using poly A oligo dT12 -18 or poly Cm oligo dG12 -18 as template primer and Mg2+ as divalent cation. This enzyme can be distinguished from other cellular DNA polymerases activities and from Terminal deoxynucleotidyl Transferase (TdT) by purification from LAV infected T lymphocytes using phosphocellulose column.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6203528     DOI： 10.1016/0006-291x(84)90696-x

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


  39 in total

1.  Structural variability of env and gag gene products from a highly cytopathic strain of HIV-1.

Authors:  N Yahi; J Fantini; I Hirsch; J C Chermann
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

2.  Expression of reverse transcriptase activity of human T-lymphotropic virus type III (HTLV-III/LAV) in Escherichia coli.

Authors:  N Tanese; J Sodroski; W A Haseltine; S P Goff
Journal:  J Virol       Date:  1986-09       Impact factor: 5.103

3.  Phenotypically Vif- human immunodeficiency virus type 1 is produced by chronically infected restrictive cells.

Authors:  M Bouyac; F Rey; M Nascimbeni; M Courcoul; J Sire; D Blanc; F Clavel; R Vigne; B Spire
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

4.  Human colon epithelial cells productively infected with human immunodeficiency virus show impaired differentiation and altered secretion.

Authors:  J Fantini; N Yahi; S Baghdiguian; J C Chermann
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

5.  The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope-mediated fusion.

Authors:  J D Reeves; T F Schulz
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

6.  Recombinant human IL-16 inhibits HIV-1 replication and protects against activation-induced cell death (AICD).

Authors:  T Idziorek; J Khalife; O Billaut-Mulot; E Hermann; M Aumercier; Y Mouton; A Capron; G M Bahr
Journal:  Clin Exp Immunol       Date:  1998-04       Impact factor: 4.330

7.  3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase.

Authors:  M H St Clair; C A Richards; T Spector; K J Weinhold; W H Miller; A J Langlois; P A Furman
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

8.  Mechanism of resistance of human immunodeficiency virus type 1 to 2',3'-dideoxyinosine.

Authors:  J L Martin; J E Wilson; R L Haynes; P A Furman
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

9.  Retroviral properties inherent to viral erythrocytic infection in sea bass.

Authors:  R M Pintó; E Ribes; J Jofre; A Bosch
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

10.  In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome.

Authors:  J K Wakefield; S A Jablonski; C D Morrow
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.